Suchergebnisse - "Touati, Nathan"

PubPharm (14)

1

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma : A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

enthalten in: Cancer | 2020

von D'Ambrosio, L. | Touati, N. | Blay, J. | +26

CommentIn: Cancer. 2020 Oct 15;126(20):4615-4616. - PMID 32767667

2

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma : A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

enthalten in: Cancer | 2020

von D’Ambrosio, L. | Touati, N. | Blay, J. | +25

3

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials

enthalten in: Acta oncologica (Stockholm, Sweden) | 2019

von Vos, M. | Sleijfer, S. | Litière, S. | +4

4

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma : revisiting the results of the EORTC-STBSG 62931 randomised trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Pasquali, S. | Pizzamiglio, S. | Touati, N. | +12

5

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Mir, O. | Touati, N. | Lia, M. | +11

6

Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial

enthalten in: Breast cancer research and treatment | 2018

von Aalders, K. | Touati, N. | Tryfonidis, K. | +7

7

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin : an updated analysis of the EORTC 62091 trial

enthalten in: Cancer medicine | 2018

von Italiano, A. | Touati, N. | Litière, S. | +3

8

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114) : an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

enthalten in: The Lancet. Oncology | 2018

von Wildiers, H. | Tryfonidis, K. | Dal Lago, L. | +8

CommentIn: Lancet Oncol. 2018 Mar;19(3):271-272. - PMID 29433964

9

Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial

enthalten in: Breast cancer research and treatment | 2018

von Aalders, K. | Touati, N. | Tryfonidis, K. | +6

10

Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial

enthalten in: Breast cancer research and treatment | 2018

von Aalders, K. | Touati, N. | Tryfonidis, K. | +6